Pulmonary Non-tuberculous Mycobacterial Infections in Category II Failures from National Tuberculosis Programme.

Pulmonary infections due to non-tuberculous mycobacteria (NTM) are increasingly being reported. These can mimic drug-resitant tubercuolosis. A diagnosis of NTM infections needs a high degree of clinical suspicion and repeated isolation of the organism on culture. NTM infections occur commonly in immunocompromised individuals and in people with lung abnormalities. Currently there are no guidelines on drug combinations and the duration of treatment is not adequately defined. Two cases of pulmonary infection with NTM in immune-competent individuals are described in the present report. Although the bacteriological, radiological and clinical response to treatment was good; early discontinuation of treatment resulted in recurrence and change in drug susceptibility pattern, suggesting the need for prolonged treatment for achieving cure.

Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation.

BACKGROUND: Pseudomonas aeruginosa, especially multidrug-resistant (MDR) isolates, is an important pathogen in allogeneic hematopoietic stem cell transplant (HCT) recipients. The ability to identify patients at risk for these infections and administer appropriate empiric therapy, particularly during episodes of neutropenia, may improve outcomes and also direct infection control and antimicrobial stewardship efforts. Many transplant centers obtain routine surveillance stool cultures (SSCs) from HCT recipients to test for colonization with vancomycin-resistant enterococci, and extended-spectrum beta lactamase-producing Enterobacteriaceae. Our center initiated the performance of SSCs for P. aeruginosa, because of a perceived increase in the frequency of infection with MDR strains. The aim of this study was to determine the utility of this practice. METHODS: We conducted a 2-year (2010-2011) retrospective review of the medical records of all patients who underwent allogeneic HCT at our cancer center to (a) determine the frequency of fecal colonization with P. aeruginosa, including MDR strains; (b) to determine the overall frequency of subsequent P. aeruginosa infection, as well as the frequency of infection with MDR strains; (c) to ascertain the proportion of subsequent infections likely arising from the intestinal tract; and (d) to determine risk factors for progression from colonization to infection. RESULTS: Of 794 study patients, 58 (7.3%) had at least 1 positive SSC for P. aeruginosa; 19/58 (32.8%) developed a subsequent pseudomonal infection (11 with matching antimicrobial resistance patterns). On the other hand, 37/736 (5%) of the patients who were not colonized, developed a pseudomonal infection. The type of infection observed was pneumonia in 26 (46%) patients, bloodstream infection in 20 (36%), urinary tract infection in 8 (14%), and infections at other sites in 2 (4%). The incidence of MDR P. aeruginosa in the entire cohort was 2.2% (18 of 794): 12 had positive SSCs and 7 of these patients later developed MDR P. aeruginosa infections. Patients with acute myelogenous leukemia were more likely to be colonized and to develop subsequent infection. No infection-related deaths were observed during the first 30 days after infection. CONCLUSIONS: The incidence of P. aeruginosa colonization and subsequent infection was low. Patients who were not colonized had a low chance of developing P. aeruginosa infection. Most patients who developed infection did not have fecal colonization, suggesting a different source of infection. SSCs for P. aeruginosa provide incomplete information regarding the source of infection.

Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice.

BACKGROUND: Hematopoietic stem cell transplant (HCT) recipients are more susceptible to infections from vaccine-preventable diseases than the general population. Despite the development of international consensus guidelines addressing immunization after HCT, studies have shown that deviations from recommended immunization practices commonly occur. METHODS: An anonymous survey aimed at determining awareness of the guidelines and attitudes toward vaccination was distributed to our HCT clinicians. In parallel, we retrospectively evaluated patients' characteristics and post-HCT vaccine administration practices from 2010 to 2013. RESULTS: The majority of survey respondents (96%) were familiar with post-HCT vaccination protocols. Seventy-four percent of respondents reported that influenza vaccines were given to >70% of their patients, and 41% stated that they prescribed live vaccines to eligible patients. However, our pharmacy database review revealed that 38% of patients received the first series of vaccinations by the recommended 6 months post HCT, and 60% received them by 1 year after HCT. Most patients who had their vaccines withheld had relapsed disease or were undergoing treatment for graft-versus-host disease. Furthermore, we identified lower immunization rates in non-English speaking individuals, African-Americans, and Hispanic patients. CONCLUSIONS: Survey respondents reported being aware of current guidelines; however, adherence to the recommendations varied, likely connected to conflicting data on vaccine effectiveness and a lack of clear recommendations in complex clinical scenarios. Similar to the general population, patient barriers also could have contributed to lower vaccination rates in some cases. To decrease the large gap between the post-HCT vaccination guidelines and clinical practice, further studies on vaccine effectiveness and specific populations are warranted.

A Newer Application of Physically Modified Gellan Gum in Tablet Formulation using Factorial Design

This study examines the physically modified gellan gum in tablet formulation i.e., as asuperdisintegrant. Physical cross-liking of gellan gum was carried out using microwave energy and itwas subjected to Differential Scanning Calorimetry and Fourier Transform – Infra Red. Swelling ratioof pure and modified gellan gum was performed. Tablets of were formulated containing modifiedgellan gum using 32 randomized full factorial designs. It was observed that physical modification ongellan gum was done by microwave energy and was confirmed by Differential Scanning Calorimetryand Fourier Transform – Infra Red. Modified gellan gum has superior swelling ratio than pure. It wasobserved that optimized batch shows excellent disintegration time (155 s), and % drug release in 2 and5 min were 39 and 78%, respectively. It was concluded that there was a no chemical interactions whileonly physical modification and modified gellan gum can work as a superdisintegrant(AU)

Evaluation of antispasmodic activity of different Shodhit guggul using different shodhan process.

According to ayurvedic texts shodhan vidhi is an important process which enhances the biological activity of a compound and reduces the toxicity at the same time. Before incorporating into formulations, guggul is processed using Shodhan vidhi involving different shodhan dravyas like gulvel, gomutra, triphala, dashmul. We have evaluated the antispasmodic activity of guggul on ileum of guinea pig and Wistar rats. The animals were sacrificed and ileum tissue of guinea pig and rat was isolated and tested for antispasmodic activity using different spasmogens like acetylcholine, histamine and barium chloride. It was observed that the different shodhit guggul (shudha guggul) i.e. processed using different shodhan vidhi, showed good antispasmodic activity as compared to Ashudha guggul. When acetylcholine was used as spasmogen, gulvel and triphala shodhit guggul showed good antispasmodic activity than other shodhit guggul. Thus shodhan vidhi enhances the therapeutic properties of guggul.

Visual acuity outcomes following vitreous loss in glaucoma and diabetic patients.

PURPOSE: To analyze the visual acuity (VA) of patients with and without vitreous loss, while concurrently analyzing the effects of the pre-existing pathologies of glaucoma and diabetes on VA. METHODS: A retrospective study on 1013 cataract extractions from 1995 to 1999 was performed. Patients included in this study had intraocular lens implantation during phacoemulsification surgery, no intraoperative complications besides vitreous loss, had no other prior ophthalmic condition other than glaucoma or diabetes, and had a postoperative follow-up interval between one and 4 months. When indicated, vitrectomy was performed concurrently with phacoemulsification following vitreous loss. Patients diagnosed with both glaucoma and diabetes were excluded. The identified subjects were then placed into six groups: (1) patients with uncomplicated surgery; (2) patients with surgery complicated by vitreous loss; (3) glaucoma patients with uncomplicated surgery; (4) glaucoma patients with surgery complicated by vitreous loss; (5) diabetic patients with uncomplicated surgery; and (6) diabetic patients with surgery complicated by vitreous loss. A two-tailed, heteroscedastic t-test and power calculation were performed on the preoperative and postoperative visual acuities of the groups. RESULTS: There were statistically significant differences (P < 0.05) in the postoperative VA between patients with and without vitreous loss at the time of surgery. Patients with the pre-surgical conditions of diabetes or glaucoma did not display a statistically significant difference in postoperative VA when compared to controls. However, the pre-surgical condition of glaucoma displayed a trend, which showed it may contribute to a poorer postoperative VA (P = 0.072, power = 0.430). CONCLUSIONS: Vitreous loss is a risk factor for a decreased postoperative VA. Also while the pre-surgical condition of glaucoma may play a role in decreasing postoperative VA, diabetes does not.

Evaluation of the polyethylene glycol-potentiated indirect antiglobulin test.

Results of the indirect antiglobulin test (IAT) potentiated by the addition of polyethylene glycol (PEG) were compared with those of the IAT performed with bovine serum albumin (BSA). This retrospective study, which encompasses 3 years, confirms that use of PEG-IAT increases the rate of detection of clinically significant red cell (RBC) antibodies, decreases the detection of insignificant antibodies, reduces the need to use other serologic enhancement techniques (such as enzyme modification of RBCs), and has a positive impact on the laboratory's workload. These advantages are provided with no diminution in the quality of service provided by the blood bank.